Harmony Biosciences Reports Strong Third Quarter 2023 Financ

Continued Strong Growth with WAKIX® Net Revenue of $160.3 Million for Third Quarter 2023; Increased ~37% Year-over-Year Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,800...

Related Keywords

United Kingdom , United States , Americans , Jeffreym Dayno , Luis Sanay , Company Updates , Harmony Biosciences Holdings Inc , Drug Administration , Paragon Biosciences , Zynerba Pharmaceuticals , Company Nasdaq , European Union , Acquisition Of Zynerba Pharmaceuticals , Exchange Commission , Million Share Repurchase Program , Continued Strong Growth , Net Revenue , Third Quarter , Pursue Idiopathic Hypersomnia Indication , Next Step , Full Data Set , Diversified Pipeline , Pivotal Phase , Common Stock , Directors Authorized New , Share Repurchase , Held Today , Biosciences Holdings , Chief Executive Officer , Commercialization Agreement , Operating Expenses , Myotonic Dystrophy , Call Today , Prescribing Information , Harmony Biosciences , Plymouth Meeting , Private Securities Litigation Reform Act , Annual Report , Biosciences Investor Contact , Biosciences Media Contact , Markets ,